Zero Candida's Significant Milestone in Expansion
Zero Candida Technologies, Inc. (TSXV: ZCT) (FSE: 9L2) has made headlines with the recent successful listing of its shares on the Frankfurt Stock Exchange (FSE). This is a proud moment for the company as it marks a critical step in enhancing its global presence. With this listing, Zero Candida now operates on both the TSX Venture Exchange and the FSE, opening doors to a wider array of international investors.
Leadership Vision and Market Response
The Founder & CEO of Zero Candida, Eli Ben Haroosh, enthusiastically remarked that joining the Frankfurt Stock Exchange is an essential advancement for the company. It signifies the growing interest from the European investment community in their innovative products aimed at women's health. This listing allows direct engagement and strengthens their mission of transforming women’s health through technology.
With ongoing partnerships with hospitals and progress in patent applications across Europe, Zero Candida is well-positioned to take full advantage of its expanded market reach. The FSE is renowned for its efficient operations and transparency in electronic trading, promising a seamless experience for international investors. This opportunity is pivotal for Zero Candida to connect with a broader range of investors globally.
Upcoming Investor Webinar Invitation
In addition to their stock exchange listing, Zero Candida is set to host an investor webinar that invites shareholders and interested parties to join virtually. Scheduled for January 22, 2025, at 1:00 PM EST (10:00 AM PST), this inaugural webinar will be an opportunity to delve into the progress of their novel device and to get an update on corporate milestones anticipated for 2025. A question and answer session will also be included, allowing participants to engage directly with the company.
How to Register for the Webinar
Participants interested in the webinar can register in advance to secure their spot. There is also an option to email the team with questions prior to the event. For those unable to attend, a recording of the session along with additional materials will be accessible later on the company's website.
Zero Candida's Commitment to Women’s Health
Zero Candida is a pioneering FemTech company engaged in innovative developments for women's health. They are in the process of creating an AI-driven device that mimics a tampon while utilizing a unique therapeutic light source to combat the Candida fungus. This device has shown a remarkable 99.999% success rate in preliminary testing with live subjects.
With vulvo-vaginal candidiasis (VVC) affecting about 75% of women globally, the need for effective treatment is more crucial than ever. Traditional methods have faced challenges such as drug resistance and lack of comprehensive understanding of the root causes. Zero Candida is actively addressing these issues, having successfully carried out safety trials in large animals and gearing up for human clinical trials with the support of key hospitals in several regions.
Innovative Solutions for Global Health Challenges
The company boasts an expanding global patent portfolio with submissions in various countries, including the United States, Brazil, and regions across Europe. Recently, they were awarded a patent in South Africa, further solidifying their position in the market. By integrating hybrid medicine with advanced diagnostics, Zero Candida strives to meet the unmet needs within women's healthcare, aiming to bring innovation into the 21st century.
Frequently Asked Questions
What is Zero Candida's main product focus?
Zero Candida focuses on developing an AI-driven medical device designed to treat Candida infections effectively.
When is the upcoming investor webinar?
The investor webinar is scheduled for January 22, 2025, at 1:00 PM EST.
How can participants register for the webinar?
Participants can register for the webinar via the registration link provided by the company or by emailing them directly with questions.
What impact does the Frankfurt listing have for the company?
The Frankfurt listing enhances Zero Candida's visibility and access to a larger pool of international investors, marking a significant step in the company's growth strategy.
How does Zero Candida support women's health?
Zero Candida aims to revolutionize women’s health by creating innovative, effective treatments for conditions like vulvo-vaginal candidiasis.
